|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...5455565758596061626364...110111» |
- | cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer (clinicaltrials.gov) - Dec 31, 2014
P1, N=31, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed
- Trial primary completion date: Human Chorionic Gonadotrophin in an Antagonist Protocol (clinicaltrials.gov) - Dec 30, 2014
P2/3, N=60, Recruiting, Sponsor: Cairo University
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Oct 2014
- Trial primary completion date: Prevalence of Polycystic Ovary Syndrome (PCOS) in Obese Premenopausal Women (clinicaltrials.gov) - Dec 30, 2014
P=N/A, N=500, Recruiting, Sponsor: Göteborg University
Trial primary completion date: May 2014 --> Oct 2014 Trial primary completion date: Sep 2014 --> Apr 2015
- | Enrollment change: Office Hysteroscopy and Endometrial Snip Improve Intrauterine Insemination Outcome (clinicaltrials.gov) - Dec 30, 2014
P3, N=332, Completed, Sponsor: Cairo University
Trial primary completion date: Sep 2014 --> Apr 2015 N=200 --> 332
- | Enrollment change: Menorrhagia Study in Women With Treatment-resistant Menorrhagia (clinicaltrials.gov) - Dec 30, 2014
P2, N=26, Completed, Sponsor: Bayer
N=200 --> 332 N=40 --> 26
- New P3 trial: The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding (clinicaltrials.gov) - Dec 30, 2014
P3, N=50, Recruiting, Sponsor: Ain Shams Maternity Hospital
- Trial primary completion date: Efficacy of Pergoveris in Aged IVF Patients (clinicaltrials.gov) - Dec 29, 2014
P=N/A, N=240, Completed, Sponsor: Vietnam National University
N=40 --> 26 Trial primary completion date: May 2013 --> Apr 2014
- | Enrollment change: Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy (clinicaltrials.gov) - Dec 29, 2014
P3, N=100, Recruiting, Sponsor: CHA University
Trial primary completion date: May 2013 --> Apr 2014 N=80 --> 100
- docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer (clinicaltrials.gov) - Dec 29, 2014
P2, N=28, Completed, Sponsor: Gynecologic Oncology Group
N=80 --> 100 N=60 --> 28
- cisplatin / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer (clinicaltrials.gov) - Dec 29, 2014
P1, N=13, Completed, Sponsor: Gynecologic Oncology Group
N=60 --> 28 N=24 --> 13
- Clinical: TORCH: Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4 (clinicaltrials.gov) - Dec 29, 2014
P=N/A, N=250, Not yet recruiting, Sponsor: Centre Hospitalier Departemental Vendee
- enoxaparin sodium / Generic mfg.
New P1 trial: Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI) (clinicaltrials.gov) - Dec 29, 2014
P1, N=40, Recruiting, Sponsor: The Egyptian IVF-ET Center
- | docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer (clinicaltrials.gov) - Dec 27, 2014
P2, N=28, Completed, Sponsor: Gynecologic Oncology Group
N=24 --> 13 Active, not recruiting --> Completed
- | cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer (clinicaltrials.gov) - Dec 27, 2014
P1, N=13, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| BRCA Biomarker: Cancer Genetics Hereditary Cancer Panel Testing (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=2000, Recruiting, Sponsor: Stanford University
- New P2 trial, Surgery: MISSION: Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study (clinicaltrials.gov) - Dec 25, 2014
P2, N=30, Recruiting, Sponsor: Catholic University of the Sacred Heart
- |||| otesaconazole (VT-1161) / Mycovia Pharma
Trial completion, Trial primary completion date: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) - Dec 25, 2014
P2, N=55, Completed, Sponsor: Viamet Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Dec 2014
- nintedanib / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Dec 25, 2014
P2, N=36, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Dec 2014 Suspended --> Active, not recruiting | N=55 --> 36 | Trial primary completion date: Nov 2014 --> Nov 2015
- || PF-06263507 / Pfizer
Trial primary completion date, Metastases: A Study Of PF-06263507 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 24, 2014
P1, N=105, Recruiting, Sponsor: Pfizer
Suspended --> Active, not recruiting | N=55 --> 36 | Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: May 2016 --> Aug 2016
- Perjeta (pertuzumab) / Roche
Trial completion date, Metastases: A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer (clinicaltrials.gov) - Dec 24, 2014
P2, N=129, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: May 2016 --> Aug 2016 Trial completion date: Jun 2005 --> Jul 2004
- Enrollment change, Trial termination, Trial primary completion date: Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=2, Terminated, Sponsor: Cook
Trial completion date: Jun 2005 --> Jul 2004 N=80 --> 2 | Recruiting --> Terminated | Trial primary completion date: Jun 2015 --> Sep 2014; Enrollment considerations and current status of the clinical study
- Enrollment change, Trial withdrawal, HEOR: Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=0, Withdrawn, Sponsor: City of Hope Medical Center
N=80 --> 2 | Recruiting --> Terminated | Trial primary completion date: Jun 2015 --> Sep 2014; Enrollment considerations and current status of the clinical study N=484 --> 0 | Not yet recruiting --> Withdrawn
- |||| Odomzo (sonidegib) / Sun Pharma
Enrollment open: Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=59, Recruiting, Sponsor: University of Alabama at Birmingham
N=484 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- Enrollment closed: SUCCESS: Using CHWs and HPV Home Tests to Increase Cervical Cancer Screening in Minority Populations (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=600, Active, not recruiting, Sponsor: University of Miami
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| pimasertib (AS703026) / Day One Biopharma
Enrollment closed, Enrollment change: EMR 200066_012: Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer (clinicaltrials.gov) - Dec 24, 2014
P2, N=65, Active, not recruiting, Sponsor: EMD Serono
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting | N=110 --> 65
- ||| afuresertib (LAE002) / Laekna Therap
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: Dose-finding Study in Platinum-Resistant Ovarian Cancer (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=60, Active, not recruiting, Sponsor: Accenture
Suspended --> Active, not recruiting | N=110 --> 65 Recruiting --> Active, not recruiting | N=43 --> 60 | Trial primary completion date: Feb 2016 --> Aug 2015
- || Enrollment closed: A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (clinicaltrials.gov) - Dec 24, 2014
P1, N=1208, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | N=43 --> 60 | Trial primary completion date: Feb 2016 --> Aug 2015 Recruiting --> Active, not recruiting
- ||| carfilzomib / Generic mfg.
P1/2 data: Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma (clinicaltrials.gov) - Dec 24, 2014
P1/2, N=184, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Active, not recruiting Completed --> Active, not recruiting | N=235 --> 184 | Trial primary completion date: Jan 2014 --> Jul 2014
- Recentin (cediranib) / AstraZeneca, RG4733 / Roche
Trial completion, Enrollment change, Metastases: Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 24, 2014
P1, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Active, not recruiting | N=235 --> 184 | Trial primary completion date: Jan 2014 --> Jul 2014 Active, not recruiting --> Completed | N=50 --> 20
- progesterone / Generic mfg.
Preclinical: Cut-Off Progesterone Values Deleterious for In Vitro Fertilization and Fresh Embryo Transfer (clinicaltrials.gov) - Dec 23, 2014
P=N/A, N=1901, Completed, Sponsor: Institut Universitari Dexeus
- menotropin / Generic mfg.
Preclinical: Ovarian Stimulation With Recombinant Gonadotropins vs. Human Menopausal Gonadotropin in In Vitro Fertilization (clinicaltrials.gov) - Dec 23, 2014
P=N/A, N=848, Completed, Sponsor: University of Turin, Italy
- Clinical: VIVROVAIRE 2: Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs. (clinicaltrials.gov) - Dec 23, 2014
P=N/A, N=120, Not yet recruiting, Sponsor: Centre Francois Baclesse
- Trial primary completion date: Surgical Success After Laparoscopic vs Abdominal Hysterectomy (clinicaltrials.gov) - Dec 19, 2014
P4, N=75, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Active, not recruiting --> Completed | N=50 --> 20 Trial primary completion date: Jun 2015 --> Jun 2016
- Clinical: 2D Versus 3D Radical Laparoscopic Hysterectomy for Endometrial Cancer: a Prospective Randomized Trial (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=36, Recruiting, Sponsor: Catholic University of the Sacred Heart
- Enrollment closed, Trial primary completion date: Randomized Clinical Trial Comparing Conventional Laparoscopic and Robot-Assisted Laparoscopic Hysterectomy (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=128, Active, not recruiting, Sponsor: Milton S. Hershey Medical Center
Trial primary completion date: Jun 2015 --> Jun 2016 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: May 2015 --> Oct 2014
- Trial primary completion date: PISH-2: A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer (clinicaltrials.gov) - Dec 19, 2014
P1, N=20, Recruiting, Sponsor: ThermalCore Inc
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: May 2015 --> Oct 2014 Trial primary completion date: Oct 2014 --> Jun 2017
- Enrollment change, Trial withdrawal: The Value of Preoperative Sentinel Lymph Node Mapping by Pelvic MR Lymphangiography and SPECT-CT in Cervical Cancer (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=0, Withdrawn, Sponsor: UMC Utrecht
Trial primary completion date: Oct 2014 --> Jun 2017 N=40 --> 0 | Not yet recruiting --> Withdrawn
- PF-04691502 / Pfizer, gedatolisib (PF-05212384) / Celcuity
Enrollment change: A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer (clinicaltrials.gov) - Dec 19, 2014
P2, N=160, Terminated, Sponsor: Pfizer
N=40 --> 0 | Not yet recruiting --> Withdrawn N=67 --> 160
- Metastases: 2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=26, Recruiting, Sponsor: Catholic University of the Sacred Heart
- Herceptin (trastuzumab) / Roche
Enrollment closed, IO biomarker: Safety Study of (clinicaltrials.gov) - Dec 19, 2014
P1, N=36, Active, not recruiting, Sponsor: Areva Med LLC
N=67 --> 160 Recruiting --> Active, not recruiting
- Trial primary completion date: Cepheid Rectal Sample Validation Study (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=550, Recruiting, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2014 --> Feb 2015
- || dydrogesterone / Generic mfg.
Observational data, Trial primary completion date: Observational Study of Dydrogesterone in Cycle Regularization (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=110, Recruiting, Sponsor: Fudan University
Trial primary completion date: Nov 2014 --> Feb 2015 Trial primary completion date: Nov 2014 --> Feb 2015
- carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
Metastases: Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=15, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Feb 2015 Trial primary completion date: Jan 2015 --> Jul 2015
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial primary completion date: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - Dec 17, 2014
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2015 --> Jul 2015 Trial primary completion date: Jan 2015 --> Apr 2015
- | progesterone / Generic mfg.
New P4 trial: Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support (clinicaltrials.gov) - Dec 16, 2014
P4, N=240, Recruiting, Sponsor: University Magna Graecia
- Trial initiation date: Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens (clinicaltrials.gov) - Dec 14, 2014
P=N/A, N=1174, Not yet recruiting, Sponsor: Centers for Disease Control and Prevention
Trial primary completion date: Jan 2015 --> Apr 2015 Initiation date: Jul 2014 --> Jan 2015
- Enrollment open, Surgery: Perioperative Assessment of Right Ventricular Function and Venous Return in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery (Gyn Right) - Pilot Study (clinicaltrials.gov) - Dec 14, 2014
P=N/A, N=30, Recruiting, Sponsor: Charite University, Berlin, Germany
Initiation date: Jul 2014 --> Jan 2015 Not yet recruiting --> Recruiting
- | Estrace topical (estradiol) / AbbVie, Estrace (estradiol) / AbbVie
New P2 trial: Vaginal Creams to Reduce Vaginal Erosion in Pessary Users (clinicaltrials.gov) - Dec 13, 2014
P2, N=246, Not yet recruiting, Sponsor: North Shore Long Island Jewish Health System
- metformin / Generic mfg.
Trial primary completion date: Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer (clinicaltrials.gov) - Dec 13, 2014
P=N/A, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Sep 2016
- | veliparib (ABT-888) / AbbVie
Trial completion: A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors (clinicaltrials.gov) - Dec 13, 2014
P1, N=45, Completed, Sponsor: AbbVie
Trial primary completion date: Sep 2015 --> Sep 2016 Active, not recruiting --> Completed